[go: up one dir, main page]

EP1641354A1 - Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales - Google Patents

Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales

Info

Publication number
EP1641354A1
EP1641354A1 EP04739586A EP04739586A EP1641354A1 EP 1641354 A1 EP1641354 A1 EP 1641354A1 EP 04739586 A EP04739586 A EP 04739586A EP 04739586 A EP04739586 A EP 04739586A EP 1641354 A1 EP1641354 A1 EP 1641354A1
Authority
EP
European Patent Office
Prior art keywords
use according
mixture
intestinal
isomalt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04739586A
Other languages
German (de)
English (en)
Inventor
Michael Klingeberg
Gunhild Kozianowski
Markwart Kunz
Stephan Theis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suedzucker AG
Original Assignee
Suedzucker AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suedzucker AG filed Critical Suedzucker AG
Publication of EP1641354A1 publication Critical patent/EP1641354A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/52—Liquid products; Solid products in the form of powders, flakes or granules for making liquid products ; Finished or semi-finished solid products, frozen granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/346—Finished or semi-finished products in the form of powders, paste or liquids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
    • A23L27/30—Artificial sweetening agents
    • A23L27/33—Artificial sweetening agents containing sugars or derivatives
    • A23L27/34—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
    • A23G2200/02—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing microorganisms, enzymes, probiotics

Definitions

  • the present invention relates to the use of a mixture of 6-O- ⁇ -D-glucopyranosyl-D-sorbitol (1,6-GPS) and 1-O- ⁇ -D-5 glucopyranosyl-D-mannitol (1,1 -GPM ) as a prebiotic and / or butyrate-providing, partially digestible and intestinal health-promoting carbohydrate in food, luxury foods, feed and / or medicines.
  • Such health-promoting foods and stimulants are intended to have their effect primarily in the digestive tract. In the anterior digestive tract, the absorbed nutrients are broken down and partially absorbed.
  • This intestinal flora includes bacteria such as Bacteroides, Eubacterium, Bifidobacte um, Lactobacillus, Atopobium and Fusobacterium.
  • Escherichia coli and optionally pathogenic microorganisms such as
  • Lactobacteria especially bifidobacteria, are known to have health-promoting properties. They produce high levels of short chain organic acids and inhibitors that limit the growth and activity of harmful bacteria,
  • ß-glucosidases which form unwanted enzymes such as ß-glucosidases, ß-glucuronidases or azoreductases.
  • ß-glucosidases The importance of some undesirable bacterial enzymes such as ß-glucosidases lies in that Formation, activation and release of toxic, carcinogenic and co-carcinogenic compounds from the body's own and exogenous substances.
  • Bacterial ß-glucosidase releases toxic aglycones from glycosides, for example.
  • Another positive property of the health-promoting intestinal flora includes immunomodulatory effects and stimulation of the immune function.
  • lactobacteria in particular bifidobacteria, also have a protective and preventive effect against intestinal infections, in particular bacterial diarrhea.
  • Short-chain fatty acids such as butyric acid (butyrate) are fermentatively formed by saccharolytic bacteria in the large intestine, in particular from undigested carbohydrates. Butyric acid is the dominant source of energy for the epithelial cells in the colon, influences cellular proliferation and differentiation and plays a central role as a growth factor for a healthy intestinal epithelium and in maintaining the mucosal barrier in the colon. Short-chain fatty acids such as butyric acid or its salts, butyrate, contribute to the detoxification of possible mutagenic metabolites in the large intestine and counteract oxidative stress, for example by inducing gene expression of protective proteins such as intestinal glutathione-S-transferase or by inhibiting ornithine. carboxylase.
  • protective proteins such as intestinal glutathione-S-transferase or by inhibiting ornithine. carboxylase.
  • short-chain fatty acids such as butyric acid have a controlling effect on the induction of specific genes and the modification of proteins of cell cycle regulation, antibacterial peptides and signal cascades.
  • This can be achieved by adding suitable substrates to improve the living conditions for the healthy intestinal flora and substrates for the microbial formation of butyric acid, also in the rear areas of the large intestine.
  • prebiotics are termed prebiotics.
  • Prebiotics promote the growth and / or activity of health-promoting intestinal bacteria and are usually carbohydrates that are not digestible by enzymes in the gastrointestinal tract.
  • prebiotics can be longer-chain carbohydrates, for example inulin or fructooligosaccharides.
  • krammel & Brokx (Cereal Foods World 46 (2001), 424-429) describe lactit in the prebiotic, but there are also known long-chain carbohydrates that do not stimulate the growth of bifidobacteria, including higher-molecular plant hemicelluloses such as xylan from larch, wheat and oats or polysaccharides of marine origin such as laminarin and alginate are primarily metabolized by the genus Bacteroides.
  • prebiotics are used to deliver butyrate, and if they do, only in the front large intestine. pass.
  • Known prebiotics such as fructooligosaccharides that reach the colon are fermented there quite quickly and completely.
  • the short-chain fatty acids formed in this way are quickly and almost completely absorbed by the intestinal epithelial cells at the point at which they arise.
  • the saccharides are fermented more slowly so that substrate can also reach the intestinal areas lying behind and are available for microbial butyrate formation.
  • a very rapid fermentation of known prebiotics can mean, among other things, a higher risk for laxative effects and other gastrointestinal ailments.
  • known prebiotics such as inulin and oligofructose are also disadvantageously characterized in that when they are broken down, other short-chain fatty acids, in particular acetic acid, are formed predominantly by the intestinal microflora and therefore only provide butyric acids to a very small extent.
  • the known prebiotics such as fructooligosaccharides are also disadvantageous in that their technological processability in food production leaves something to be desired.
  • a lack of water solubility, for example in the case of longer-chain carbohydrates such as resistant starch, their low acid stability and their reactivity as partially reducing oligosaccharides contribute to their limited applicability. This is especially true when used in products that have a low pH.
  • the known prebiotics are further disadvantageous in that they are fermented comparatively quickly and / or lead to only a slight formation of butyric acid and are therefore only slightly butyrogenic.
  • the present invention is therefore based on the technical problem of providing substances or substance mixtures which take on prebiotic functions in food, luxury foods, feeds and pharmaceuticals and at the same time support the formation of butyric acid can and thereby overcome the aforementioned disadvantages, in particular with the best possible processability, advantageous nutritional parameters and good tolerability, act as bifidogenic prebiotics and serve as a butyrate-non-butyrenic substrate.
  • the present invention solves the technical problem on which it is based by providing a use of mixtures of 1,6-GPS and 1,1-GPM in food, luxury foods, feed and pharmaceuticals as a prebiotic, in particular a bifidogenic prebiotic and / or as a fermentable substrate, in particular as a non-butyrate and at the same time slower fermentable substrate, with good technological processability.
  • the present invention is based inter alia on the fact that the mixture of 1,6-GPS and 1,1-GPM. used in food, luxury foods, feed and pharmaceuticals after consumption in the gastrointestinal tract of human or animal consumers has prebiotic, in particular bifidogenic activity and / or serves as a substrate for the formation of butyric acid.
  • the investigations of the mixture used according to the invention surprisingly showed that consumption of a mixture of 1,6-GPS and 1,1 -GPM leads to an increase in good and health-promoting bacteria, in particular bifidobacteria in the intestinal tract of the consumer, which can be demonstrated, for example, by an increase in bifidobacteria in the stool flora.
  • the mixture used according to the invention is characterized in that consumption by the consumer also leads to an increase in the proportion of bifidobacteria in the total flora.
  • the mixture used according to the invention can be consumed by humans in larger quantities, for example of 30 g / d and more, with the daily diet without causing gastrointestinal inconveniences.
  • bifidobacteria can grow and degrade with isomalt and thereby form short-chain fatty acids. It was also possible to show that the mixture used according to the invention is also suitable as the only preferred carbon and energy source for bifidobacteria.
  • Bifidobacteria or “bifidus flora” refers to a genus of gram-positive, immobile, immobile, sporeless, and anaerobic rod bacteria, in particular of the species B. adolescentis, B. bifidum, B. breve, B. catenulatum, which colonizes the large intestine. B. longum and B. infantis understood.
  • Bifidobacteria are bacteria that are particularly desirable for human before health is considered.
  • Bifidobacteria are considered to be important carriers of colonization resistance to pathogenic bacteria and antagonists of putrefactive flora.
  • By the fermentative production of short-chain fatty acids in the large intestine and inhibitors they contribute to the inhibition of the growth of harmful bacteria and their activity, for example by inhibiting harmful bacterial enzymes such as ⁇ -glucosidase.
  • bifidobacteria By inhibiting pathogenic bacteria, bifidobacteria also have a protective and preventive effect against infections, in particular bacterial intestinal infections. By producing short-chain fatty acids in the large intestine, bifidobacteria contribute to the nutrient supply and maintenance of the large intestinal mucosa.
  • bifidobacteria cannot or only to a limited extent be used in foods, i.e. probiotic foods, because of their sensitivity to atmospheric oxygen.
  • probiotic cultures By combining probiotic cultures and the mixture used according to the invention as a prebiotic substance, an improved survival of the living bacteria in synbiotic products can be achieved, as well as the stimulation of both supplied and, in particular, endogenously present positive bacteria such as bifidobacteria in the entire intestinal tract.
  • the mixture used according to the invention is also metabolized more slowly by human intestinal flora and leads to higher butyrate production than, for example, the known prebiotic fructans.
  • the mixture used according to the invention which is consumed with food, reaches the rear areas of the large intestine to a greater extent and can be used there as an active ingredient, for example for treatment or prevent colon diseases.
  • the mixture used according to the invention is further characterized by an extremely good technological processability in food, enjoyment and animal feed, also due to its water solubility and acid stability.
  • the acid stability makes the use according to the invention particularly suitable for products which have a low pH.
  • the use of the mixture mentioned according to the invention is also advantageously distinguished in that it can be used in humans and animals to support and stabilize healthy intestinal flora, to promote healthy intestinal flora metabolism, to maintain healthy intestinal epithelium, to support intestinal health. for the reduction of toxic and damaging intestinal contents, for the prevention and treatment of inflammatory bowel diseases and / or for the prevention of colon cancer and other diseases of the intestinal epithelium.
  • the mixture can be used for the prevention and control of infectious diseases, in particular also bacterial intestinal infections and diarrheal diseases, and for modulating and supporting the immune system, as a substance with properties of soluble fiber and / or as a substance with prebiotic properties.
  • the mixture used in the use according to the invention advantageously reaches the large intestine, where it then serves as a substrate for the microorganisms present there, such as lactobacteria, in particular bifidobacteria, and is fermented to give short-chain fatty acids.
  • lactobacteria in particular bifidobacteria
  • the short-chain fatty acids produced by the bifidobacteria and inhibitors result in an inhibition of the harmful bacteria and their activity, which in particular also shows a reduction in the activity of the microbial ⁇ -glucosidase, which releases toxic and carcinogenic compounds.
  • the mixture according to the invention therefore has bifidogenic and prebiotic properties.
  • the isomalt according to the invention is also fermented comparatively slowly by the human intestinal flora and promotes the saccharolytic microflora. High concentrations of butyric acid in the colon support a healthy intestinal environment, improve symptoms of ulcerative inflammation of the colon and are protective in colon carcinogenesis.
  • Butyric acid serves as a growth factor for a healthy intestinal epithelium and as a substrate for the colon cells and thus counteracts the development and growth of colon carcinomas, among other things. Butyric acid contributes to the detoxification of possible mutagenic metabolites in the colon and counteracts oxidative stress, for example by inducing protective proteins such as intestinal glutathione-S-transferase or by inhibiting ornithine decarboxylase.
  • a healthy intestinal environment prevents negative effects such as diarrhea, Constipation, inflammation and the passage of unwanted substances and bacteria from the intestinal lumen into the body.
  • the use according to the invention of the mixture used has a positive effect on the health of humans and animals, in particular by increasing the quantity and the proportion of lactobacteria, in particular bifidobacteria in or on the intestinal flora, and the slower fermentation and, at the same time, high butyric acid formation by the saccharolytic intestinal flora ,
  • the use according to the invention of the mixture used serves to support and stabilize healthy intestinal flora, to promote healthy intestinal flora metabolism, to maintain healthy intestinal epithelium, to maintain intestinal health, to reduce toxic and harmful intestinal contents, to reduce oxidative stress, prevention and treatment of inflammatory bowel diseases, prevention of colon cancer, especially colon cancer, also in the back of the intestine and other diseases of the intestinal epithelium.
  • the mixture serves to prevent and combat infectious diseases, especially bacterial intestinal infections, and to modulate and support the immune system.
  • a “prebiotic” is understood to mean a food, luxury food, feed or pharmaceutical component which selectively controls the growth and / or the activity of specific bacteria in the human or animal digestive tract, in particular bifidobacteria and / or lactobacilli stimulated in such a way that health-promoting effects can be expected.
  • Prebiotics are usually not digestible or difficult to digest.
  • a “probiotic” is understood to mean a living microbial constituent of a food, luxury food, feed or pharmaceutical, which is stabilized or improved in the microbial composition in the The human or animal consumer’s digestive tract promotes their health.
  • probiotic microorganisms that can be used in food, pharmaceuticals or feed are, for example: Bifidobacterium such as the strains B. adolescentis, ß. animalis, B. bifidum, B. longum, B. thermophilum; Enterococcus; Lactobacillus such as the strains Lb. acidophilus, Lb. brevis, Lb. casei, Lb. cellobiosus, Lb. crispatus, Lb.
  • Preferred probiotics are bacteria of the genera Lactobacillus and Bifidobacterium.
  • “synbiotic” is understood to mean a mixture of at least one prebiotic and at least one probiotic, which improves the survival rate and increases the number of health-promoting living microbial organisms in the gastrointestinal tract, the health of human or animal Promotes consumers, especially by selectively stimulating the growth and / or metabolic activity of the microbial organisms.
  • Food or “feed” are understood to mean primarily substances or mixtures of substances in solid, liquid, dissolved or suspended form which serve human or animal nutrition.
  • a stimulant is primarily understood to mean substances or mixtures of substances in solid, liquid, dissolved or suspended form which serve the enjoyment of the human or animal body when consumed.
  • a medicinal product is mainly used for the prophylaxis or therapy of diseases, disorders, injuries or signs of aging in the human or animal body. understood mixtures in solid, liquid, dissolved or suspended form.
  • illness or “illness” is understood to mean a disruption of life processes and / or deficiency states in organs or in the entire organism which brings about a subjectively perceived and / or an objectively ascertainable physical and / or psychological change ,
  • active substance is understood to mean a substance that can produce a biological effect in living organisms or parts thereof. This active ingredient can serve in particular for the prevention, relief, healing or diagnosis of a disease.
  • a “therapeutic agent” is understood to mean a substance which serves for the prevention or prophylaxis, relief or healing of an illness.
  • “medicament” is understood to mean a preparation of active substances intended for use in humans or animals.
  • the invention relates to a use, in which use the mixture of 1,6-GPS and 1,1-GPM is isomalt.
  • isomalt is understood to mean the mixture of 1,6-GPS and 1,1-GPM, also referred to as palatinite, for example a mixture which contains 43 to 57% by weight of 1,6-GPS and 57 to 43 wt .-% 1, 1-GPM, based on the dry matter of the mixture contains.
  • the mixture used according to the invention consists of 1,6-GPS and 1, 1 -GPM, essentially consists of or contains them.
  • the mixture is preferably a 1,6-GPS-enriched or a 1,1-GPM-enriched mixture or contains this, so as described in DE 195 32 396 C2, which is completely included in the disclosure content of the present teaching with regard to the production and composition of the mixtures enriched in 1,6-GPS and 1,1-GPM.
  • the mixture of 1,6-GPS and 1,1-GPM used in a food, luxury food, feed or pharmaceutical according to the invention is the only prebiotic and / or the only butyrogenic substrate and / or as the only sweetener in the food, edible, feed or pharmaceutical.
  • the mixture of 1,6-GPS and 1, 1-GPM contains further substances or substance mixtures, for example 1,1-GPS (1-O- ⁇ -D-glucopyranosyl-D-sorbitol).
  • the mixture used in accordance with the invention can also contain mannitol, sorbitol, hydrogenated or non-hydrogenated oligosaccharides.
  • polydextrose Fructoooligosaccharides with short and long saccharide chains, for example ß (2 ⁇ 1) fructans, for example from extraction from chicory root and possible subsequent partial hydrolysis, or from transfructosylation of sucrose
  • Galacto-oligosaccharides and transgalactosylated oligosaccharides for example by transgalactosylation of lactose such as 6 'galactosyllactose (with Aspergillus oryzae ⁇ -galactosidase) or 4' Galactosyl lactose (with Cryptococcus laurentii or Bacillus circulans ß-galactosidase); partially hydrolyzed guar gum, such as "Sunfibre” or "Benefibre”;lactulose;lactitol;maltitol;sorbitol;mannito
  • Resistant starch such as "Neo-Amylose” or “Actistar” fibers from oats, wheat, vegetables, for example tomato or pea, fruits, for example apple, various berries, fruits of the carob tree, fibers from sugar beet, such as " Fibrex "from Danisco, from fruits of the carob tree, such as” Caromax “from Nutrinova, or cellulose or Vitacel from Rethenmaier.
  • the mixture of 1,6-GPS and 1,1-GPM used according to the invention optionally in a mixture with one of the aforementioned fibers, in particular substances with a prebiotic and / or butyrogenic effect, additionally contains at least one probiotic, for example Bacteria of the genus Lactobacillus and / or Bifidobacterium, for example Bacillus cereus toyoi; Bacillus cereus; Bifidobacterium as the strains: B. adolescentis, B. animalis, B. bifidum B. longum, B. thermophilum; Enterococcus; Lactobacillus such as the strains Lb. acidophilus, Lb.
  • probiotic for example Bacteria of the genus Lactobacillus and / or Bifidobacterium, for example Bacillus cereus toyoi; Bacillus cereus; Bifidobacterium as the strains: B. adolescentis, B. animalis,
  • the mixture of 1,6-GPS and 1,1-GPM is therefore used in a particularly preferred embodiment as part of a synbiotic.
  • a combination of a probiotic and the mixture used according to the invention, in particular isomalt, as a prebiotic can advantageously achieve better survival of the probiotic bacteria during passage through the upper gastrointestinal tract and an improved success rate in the settlement of the probiotic bacteria in the intestinal tract, in particular the large intestine become.
  • the prebiotic mixture used according to the invention increases the growth and activity of both the exogenously supplied probiotic and the endogenously present bacteria, in particular bifidobacteria.
  • the mixture of 1,6-GPS and 1, 1-GPM used according to the invention in a food, luxury food, feed or pharmaceutical is preferably used as a prebiotic, in particular bifidogenic prebiotic and / or as butyrogenic, slowly fermentable substrate used.
  • a higher concentration of butyric acid (butyrate) is obtained by activating saccharolytic bacteria in the large intestine due to the butyrogenic and slower fermentation of the mixture used according to the invention, in particular isomalt.
  • this mixture can contain other additives and auxiliaries such as preservatives, colors, flavors, aromas, food-compatible acids, intensive sweeteners, emulsifiers, lubricants and release agents, medicinal substances, vitamins, coenzymes, minerals or trace elements.
  • auxiliaries such as preservatives, colors, flavors, aromas, food-compatible acids, intensive sweeteners, emulsifiers, lubricants and release agents, medicinal substances, vitamins, coenzymes, minerals or trace elements.
  • the mixture used according to the invention is used in foods such as milk products and milk products, such as cheese, butter, yoghurt, drinking yoghurt, kefir, quark, sour milk, buttermilk, cream, condensed milk -, dry milk, whey, milk sugar, milk protein, milk mix, milk semi-fat, whey mix, or milk fat products or preparations; Bakery products, in particular bread, rolls, croissants including biscuits or pastries including long-life baked goods, biscuit products or waffles; Spreads, margarine products or shortenings; Instant products and broths; Fruit products or fruit preparations such as jams, jams, jellies, gelling sugar, canned fruit, fruit pulps, fruit pulp, fruit juices, fruit concentrates, fruit nectar or fruit powder; Vegetable products or preparations such as canned vegetables, vegetable juices or vegetable pulp; Spice mixes; Muesli or muesli mixtures, as well as products containing prepared muesli; non-alcoholic
  • Another preferred object of the present invention is the use of the mixture used according to the invention as an active ingredient, in particular as a therapeutic active ingredient, in particular in medicaments, medicament-like preparations, foodstuffs, foodstuffs and / or luxury foods and as an additive in animal feedstuffs for the treatment of diseases ,
  • these are pharmaceutical compositions, a medicament which contains the isomalt according to the invention, and the use of the isomalt according to the invention for the production of such medicaments.
  • the mixture used according to the invention is used as an active ingredient for the treatment of intestinal diseases.
  • the mixture used according to the invention is used as an active ingredient for restoration and stabilization.
  • mixture used according to the invention is used in particular in animal feed, both in the small animal and in the large livestock sector.
  • the invention also relates to the use of the mixture used according to the invention as an active ingredient, optionally together with at least one of the abovementioned additives and auxiliaries, such as further prebiotics or indigestible carbohydrates, in particular fiber or substances with a fiber-like effect, or probiotics, in a medicament or for the preparation a medicament for combating and / or prophylaxis of disease states, disorders, injuries or signs of aging, in particular also diseases and disorders of the gastrointestinal tract, the human or animal body.
  • additives and auxiliaries such as further prebiotics or indigestible carbohydrates, in particular fiber or substances with a fiber-like effect, or probiotics, in a medicament or for the preparation a medicament for combating and / or prophylaxis of disease states, disorders, injuries or signs of aging, in particular also diseases and disorders of the gastrointestinal tract, the human or animal body.
  • the mixture used according to the invention is used alone or preferably together with other substances in the food, luxury foods, feed or pharmaceuticals in solid, for example crystalline but also amorphous, ground or liquid, in particular suspended or dissolved form.
  • Suitable suspension or solvents are food-compatible solvents, in particular water, alcohols and mixtures thereof. Further advantageous refinements of the present invention result from the subclaims.
  • FIG. 1 shows a comparison of the total activity of microbial ⁇ -glucosidase in stool samples from subjects with isomalt consumption or with placebo consumption.
  • FIG. 2 shows breakdown rates of fructooligosaccharides (FOS) and isomalt in the in-fermentation with human intestinal bacteria.
  • FIG. 3 shows in the form of a histogram the formation of butyrate in the in-yro fermentation of isomalt and FOS.
  • the stool was quantitatively collected and, based on the stool samples obtained, the qualitative and quantitative composition of the stool flora and thus also the change in individual bacterial species in relation to the total flora was determined microbiologically.
  • the microbial faecal flora without consuming isomalt was compared with the faecal flora when consuming isomalt. In this way, differences and changes due to isomalt consumption could be recorded in each individual.
  • FISH fluorescence in situ hybridization
  • Table 1 Comparison of the bacterial numbers in human stool samples after consumption of 30 g / day isomalt or placebo over four weeks.
  • the bifidogenic effect of isomalt was determined from a comparison of the bifidobacteria in stool samples for all subjects in the study without isomalt consumption compared to stool samples when isomalt consumption.
  • Table 2 Number of bifidobacteria and percentage of bifidobacteria in total bacteria in human stool samples after consumption of 30 g / day isomalt or placebo over four weeks.
  • the results of the microbiological examination of the stool samples using the FISH technique revealed significantly more bifidobacteria in stool samples per day with isomalt consumption compared to placebo (10.3 vs 6.9 x 10 11 bifidobacteria; p ⁇ 0.05).
  • the proportion of bifidobacteria in total bacteria in stool samples was around 30% higher with isomalt.
  • consumption of products containing isomalt leads to a significant increase in the number of bifidobacteria in stool samples and the proportion of bifidobacteria in the total flora.
  • stimulation of the growth of bifidobacteria with isomalt consumption was found in the studies.
  • Example 2 Effect of isomalt on the activity of the microbial enzyme ⁇ -glucosidase
  • the reaction mixture of 1500 ⁇ l buffer, 400 ⁇ l substrate (0.01 mol / l) and the stool sample was incubated for 1 h at 37 ° C., after 60 min 1 ml stop reagent (glycine buffer 0.1 mol / l pH 12.0) added and the intensity of the resulting yellowing at a wavelength of 405 nm was determined photometrically. The intensity is proportional to the activity of the enzyme. The activity of the enzyme is given as the released product [ ⁇ mol] per sample [g] per unit of time [h].
  • consumption of isomalt leads to a significant reduction in the overall activity of the microbial ⁇ -glucosidase in stool samples.
  • the average before total ⁇ -glucosidase activity reduced by 40.3%.
  • the reduction in the microbial ⁇ -glucosidase shows that isomalt inhibits the harmful microorganisms and / or inhibits their activity. Since the release of potentially carcinogenic and toxic aglycones is being discussed for the microbial ß-glucosidase, this is regarded as a protective effect for keeping the intestine and the intestinal function healthy.
  • Example 3 Degradation of isomalt by bifidobacteria
  • the individual strains were incubated for 48 hours at 37 ° C. in hunger tubes under anaerobic conditions under an atmosphere of 80% / 20% N 2 / CO 2 and then inoculated again on the same nutrient medium.
  • the cultures were then inoculated onto hunger tubes with an identical medium which contained isomalt as the only substrate. After an incubation time of 48 h at 37 ° C., a second transfer to the same medium with isomalt took place.
  • Table 3 shows the results of isomalt degradation, growth based on the increase in optical density, and the formation of lactate and acetate.
  • Example 4 Comparison of the degradation rate of isomalt and fructooligosaccharides during in-fermentation with human intestinal bacteria
  • a 10% faecal suspension was prepared from stool samples from test subjects under anaerobic conditions in 50 mmol / l phosphate buffer, pH 7.0 and this was used to inoculate the following nutrient medium: Trypton 1.5 g
  • Vitamin solution (according to DSM 141) 0.5 ml
  • fructooligosaccharides used in in vitro fermentation experiments were completely metabolized within approx. 8 h; in the case of fermentation experiments with isomalt, no carbohydrate was detectable until after 14 h.
  • fructooligosaccharides During the in vitro fermentation of isomalt, significantly higher concentrations of butyrate were formed (14.2 mmol / l). In the fermentation of fructooligosaccharides, only 2.5 mmol / l butyrate were synthesized (FIG. 3). Isomalt is metabolized more slowly by human intestinal flora and leads to higher butyrate production than fructooligosaccharides.
  • Boil isomalt and water in the candy cooker to 155-160 ° C. Vacuum for 5 min under full vacuum. Cool the mass to 110-115 ° C. Addition of acid, aroma, color solution. The melt is stamped or poured.
  • Boil isomalt, maltitol syrup and water to 132-136 ° C (depending on the desired consistency).
  • Add the gelatin solution. Add vegetable fat, emulsifier, citric acid, and color in the order listed and mix at high speed for 2-3 minutes a homogeneous mixture is achieved.
  • Dog cookies Mix the ingredients, form small balls and bake at 200 ° C for about 20 minutes. Dog cookies
  • Probiotic strain 0.01 g e.g. Pediococcus acidilactici
  • Citric acid 3.8 g
  • Wheat flour type 550 400.00 g
  • Wheat flour type 550 1000.0 g
  • Wheat flour type 550 300.00 g
  • Suspensions of milk, isomalt, salt, citric acid and leavening agent are kneaded with half the flour to a pre-batter. Then make the main dough from pre-batter, fat and remaining flour. Kneading time, pre-dough 7 min, main dough: 13 min, dough resting time: approx. 20 min. Baking temperature: temperature curve of 200 ° C, 300 ° C, 270 ° C. Baking time approx. 6 min when using a continuous oven.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne une nouvelle utilisation d'un mélange de 6-O-a-D-glucopyranosyl-D-sorbite et de 1-O-a-D-glucopyranosyl-D-mannite comme prébiotique bifidigène, renfermant éventuellement un prébiotique, pour l'utilisation en tant que produit alimentaire, condiment, produit alimentaire pour animaux, ou en tant que médicament, et/ou pour la fabrication de tels produits, le médicament étant utilisé entre autres, pour le traitement et/ou la prophylaxie de maladies intestinales, telles que, par exemple, les maladies intestinales inflammatoires chroniques, le cancer de l'intestin, les infections intestinales bactériennes.
EP04739586A 2003-06-16 2004-06-04 Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales Withdrawn EP1641354A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10328180A DE10328180A1 (de) 2003-06-16 2003-06-16 Verwendung von Isomalt als Präbiotikum
PCT/EP2004/006030 WO2004112505A1 (fr) 2003-06-16 2004-06-04 Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales

Publications (1)

Publication Number Publication Date
EP1641354A1 true EP1641354A1 (fr) 2006-04-05

Family

ID=33520831

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04739586A Withdrawn EP1641354A1 (fr) 2003-06-16 2004-06-04 Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales

Country Status (15)

Country Link
US (1) US20060147500A1 (fr)
EP (1) EP1641354A1 (fr)
JP (1) JP4451879B2 (fr)
KR (1) KR20060030042A (fr)
CN (1) CN1802101B (fr)
AU (1) AU2004248895A1 (fr)
BR (1) BRPI0411528A (fr)
CA (1) CA2527765A1 (fr)
DE (1) DE10328180A1 (fr)
EA (1) EA200600041A1 (fr)
IL (1) IL171938A0 (fr)
MX (1) MXPA05013815A (fr)
NO (1) NO20060185L (fr)
WO (1) WO2004112505A1 (fr)
ZA (1) ZA200509146B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082104A1 (en) * 2004-08-12 2007-04-12 Sophie De Baets Functional sugar replacement
EP1817964A1 (fr) * 2006-02-13 2007-08-15 Sweetwell NV Remplacement fonctionnel de sucre
EP1629730A1 (fr) * 2004-08-12 2006-03-01 First-to-Market N.V. Remplacement fonctionnel de sucre
DE102005010833B4 (de) * 2005-03-07 2015-04-09 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Verfahren zur Herstellung eines glasierten oder gefrosteten Cerealienproduktes mit einem Kern aus Cerealien und einer Beschichtung
US7572474B2 (en) * 2005-06-01 2009-08-11 Mead Johnson Nutrition Company Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
EP1790237A1 (fr) * 2005-11-02 2007-05-30 Compagnie Gervais Danone Émulsion alimentaire pour utilisation dans des barres, fourrures, couvertures et produits tartinables et procédé de préparation
US8524304B2 (en) * 2005-11-23 2013-09-03 The Coca-Cola Company High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith
GB0524128D0 (en) * 2005-11-28 2006-01-04 Barry Callebaut Ag Compositions
JP5214464B2 (ja) 2005-12-28 2013-06-19 アドバンスド バイオニュートリション コーポレーション 多糖類、糖類およびポリオール類の乾燥マトリックスを含む、ガラス形態の、プロバイオティクス細菌用送達媒体およびその製造方法
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
DE102006014543A1 (de) * 2006-03-21 2007-09-27 Südzucker AG Mannheim/Ochsenfurt Funktionelle Lebensmittel gegen Tumore
GB0615781D0 (en) * 2006-08-09 2006-09-20 Coressence Ltd Prebiotic composition
DE102006040456A1 (de) * 2006-08-25 2008-02-28 Constantin Nies Verzehrbare flächige Darreichungsform von Nahrungsergänzungsmitteln und/oder Arzneiwirkstoffen zur Ergänzung von fertigen oder halbfertigen Nahrungsmitteln
CN101534656B (zh) 2006-11-07 2013-05-22 宝洁公司 包含纤维的组合物及其制备和使用方法
WO2008076975A1 (fr) * 2006-12-18 2008-06-26 Advanced Bionutrition Corporation Produit alimentaire sec contenant un probiotique vivant
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same
US20090011079A1 (en) * 2007-07-02 2009-01-08 Bestsweet, Inc. Hard Coated Confectionary Having A Consumable Soft Chewing Core With An Active And Method For Making Same
WO2009078495A1 (fr) * 2007-12-19 2009-06-25 Kirin Holdings Kabushiki Kaisha Matière contenant des fibres alimentaires insolubles provenant de grains de céréales
JP5606672B2 (ja) * 2008-11-26 2014-10-15 太陽化学株式会社 シンバイオティクスを利用した腸内環境調整方法
CA2986751A1 (fr) 2009-03-27 2010-09-30 Intervet International B.V. Vaccins microparticulaires utilisables pour proceder a une vaccination et a des rappels par voie orale ou nasale chez les animaux, dont les poissons
AU2010254235B2 (en) 2009-05-26 2015-04-02 Advanced Bionutrition Corporation Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
US20120156185A1 (en) * 2009-08-31 2012-06-21 Herbamed Ltd. Nutritional compositions comprising citrus fibers
EP2332426A1 (fr) * 2009-12-11 2011-06-15 Technische Universität Graz Prébiotique
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
CA2785815C (fr) 2010-01-28 2018-04-24 Advanced Bionutrition Corporation Composition vitreuse seche comprenant un materiau bioactif
US20110189342A1 (en) * 2010-02-01 2011-08-04 Jeong Hea-Seok High-purity galactooligosaccharides and uses thereof
JP5800527B2 (ja) * 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
ES2676656T3 (es) 2010-08-13 2018-07-23 Advanced Bionutrition Corp. Composición estabilizante de almacenamiento en seco para materiales biológicos
CN102450536A (zh) * 2010-10-28 2012-05-16 纽威(武汉)生物科技有限公司 用来抑制食欲和排毒减肥消脂的组合物
FR2974512B1 (fr) * 2011-04-28 2013-11-08 Roquette Freres Composition anti-inflammatoire de l'intestin comprenant du maltitol
AR087157A1 (es) 2011-06-20 2014-02-26 Gen Biscuit Galletita saludable
JP5931449B2 (ja) * 2012-01-11 2016-06-08 日東電工株式会社 医薬組成物及びその製造方法
CN104126747B (zh) * 2014-07-14 2018-08-07 赵亮 多聚功能糖和食品组合物以及它们的制备方法
CN104642689A (zh) * 2015-03-05 2015-05-27 宜兰食品工业股份有限公司 一种无糖蜜饯及其制备方法
KR102685914B1 (ko) 2015-07-29 2024-07-16 어드밴스드 바이오뉴트리션 코프. 특수 식이 용도를 위한 안정한 프로바이오틱 건조 조성물
US11166968B2 (en) 2015-09-29 2021-11-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
CN105995058B (zh) * 2016-05-27 2020-04-10 中国农业科学院饲料研究所 一种反刍动物代乳品或开食料中植物蛋白替代品及其应用
KR101848230B1 (ko) * 2016-11-21 2018-05-28 롯데제과 주식회사 락토바실러스 균주의 안정성 증진을 위한 프리바이오틱스 조성물 및 이를 이용한 안정화 증진방법
RU2748651C2 (ru) 2017-02-28 2021-05-28 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
IT201700099708A1 (it) * 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio
CN107927178A (zh) * 2017-11-16 2018-04-20 广州硕维食品技术有限公司 一种快速发酵的酸奶粉及其制备方法
US11850270B2 (en) * 2017-12-04 2023-12-26 The BioCollective, LLC Probiotics and methods of use
KR102236944B1 (ko) * 2020-04-29 2021-04-06 (주)네오크레마 갈락토올리고당, 또는 갈락토올리고당 및 콜라겐 트리펩타이드를 포함하는 면역기능 개선 및 피부상태 개선용 기능성 식품조성물 및 화장료 조성물
KR102365680B1 (ko) * 2021-09-09 2022-02-24 주식회사 베러댄베러 유산균 순간증착 기법을 이용해 유산균 함유량을 극대화하는 마쉬멜로의 제조방법 및 이를 이용하여 제조한 마쉬멜로
TWI817342B (zh) * 2022-01-27 2023-10-01 大江生醫股份有限公司 益生質組合物及其用途
EP4324465A1 (fr) * 2022-08-15 2024-02-21 Gedea Biotech AB Composés destinés à être utilisés dans le traitement d'une infection microbienne dans le système urogénital

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI108512B (fi) * 1997-08-22 2002-02-15 Danisco Finland Oy Tahnamainen nautittavaksi tarkoitettu koostumus, sen käyttö ja sitä sisältävät tuotteet
DE19818842C1 (de) * 1998-04-28 2000-01-05 Suedzucker Ag Erkältungsmittel
CN1136783C (zh) * 1999-08-30 2004-02-04 Wm.雷格利Jr.公司 使用氢化异麦芽寡糖混合物的食品涂敷方法
DE19943496C1 (de) * 1999-09-10 2001-05-17 Suedzucker Ag Direkt verpressbarer Rohstoff für Komprimate
DE19943491B4 (de) * 1999-09-10 2010-04-01 Südzucker AG Mannheim/Ochsenfurt Verbesserte Komprimate
DE10104055A1 (de) * 2001-01-31 2002-08-14 Suedzucker Ag Verwendung von Kohlenhydraten zur Beseitigung von Darminfektionen bei Tieren
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004112505A1 *

Also Published As

Publication number Publication date
DE10328180A1 (de) 2005-01-13
WO2004112505A8 (fr) 2005-03-24
BRPI0411528A (pt) 2006-08-01
JP2006527586A (ja) 2006-12-07
CN1802101B (zh) 2010-04-28
NO20060185L (no) 2006-03-15
CA2527765A1 (fr) 2004-12-29
ZA200509146B (en) 2007-03-28
CN1802101A (zh) 2006-07-12
AU2004248895A1 (en) 2004-12-29
EA200600041A1 (ru) 2006-06-30
JP4451879B2 (ja) 2010-04-14
IL171938A0 (en) 2006-04-10
WO2004112505A1 (fr) 2004-12-29
US20060147500A1 (en) 2006-07-06
MXPA05013815A (es) 2006-03-13
KR20060030042A (ko) 2006-04-07

Similar Documents

Publication Publication Date Title
EP1641354A1 (fr) Utilisation d'isomalt (melange de 1,6 gps et de 1,1 gpm) comme prebiotique, en particulier pour la fabrication d'un medicament destine au traitement de maladies intestinales
EP1513942B1 (fr) Galactosyl-isomalte, son procede de preparation et son utilisation
EP1465505B1 (fr) Stimulation du systeme immunitaire avec du polydextrose
DE10262018B4 (de) Zusammensetzungen, Nahrungs-, Lebens-, und Genussmittel, Süßwaren, Tierfuttermittel, diätische Spezial-Ernährung, Kinderernährung, Süßungsmittel und pharmazeutische Zusammensetzungen enthaltend kondensierte Palatinose
EA014269B1 (ru) Сахарозаменяющая композиция, способ её получения и её применение в изготовлении пищевых продуктов
DE102005046237A1 (de) Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
DE10242062B4 (de) Hydrierte kondensierte Palatinose, Verfahren zu deren Herstellung und deren Verwendung
EP1998633A1 (fr) Aliment fonctionnel contre les tumeurs
DE69333587T2 (de) Bifidobacterium wachstumspromotor
IL165448A (en) Galactosyl isomalt compositions and methods for producing galactosyl isomalt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060116

Extension state: LT

Payment date: 20060116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20141006